Ra Pharma (RARX) PT Raised to $34 at BMO Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/3/2026
- Wall St ends higher as stocks reclaim some shine
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Snowflake soars 20% on earnings beat and raised guidance
- Oil settles 1% higher, as US-Iran strikes threaten supplies
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
Ra Pharma (RARX) PT Lowered to $18 at RBC Capital, 'RA101495 ph2 PNH update narrows market but looks viable'
December 5, 2017 10:17 AM ESTRBC Capital lowered its price target on Ra Pharma (NASDAQ: RARX) to $18.00 (from $21.00) while maintaining a Outperform rating.
Analyst Kennen MacKay lowers his PT as the market appears narrower but retains his Outperform recommendation as the drug appears viable. The analyst... More
Ra Pharmaceuticals (RARX) Reports Positive Interim Results from Phase 2 Study of RA101495 SC in PNH
December 4, 2017 7:02 AM ESTRa Pharmaceuticals, Inc. (NASDAQ: RARX) today announced positive interim results from the Companys ongoing, global Phase 2 clinical program evaluating RA101495 SC for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Ra Pharma is a clinical stage biopharmaceutical company focusing on the development of next-generation therapeutics for the treatment of complement-mediated diseases and is developing RA101495 as a novel,... More
